Diese Webseite benutzt Cookies um das Angebot zu verbessern. Mehr Informationen

Publikationen aus der Klinik

Publikationen aus der Klinik für Hämatologie, Onkologie und Palliativmedizin

Im Jahr 2016

  • Baertsch, M.-A., Schlenzka, J., Mai, E.K., Merz, M., Hillengaß, J., Raab, M.S., Hose, D., Wuchter, P., Ho, A.D., Jauch, A., Hielscher, T., Kunz, C., Luntz, S., Klein, S., Schmidt-Wolf, I.G.H., Görner, M., et.al.: Rationale and design of  the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer (2016) 16:290,  DOI 10.1186/s12885-016-2321-2
  • Al-Batran, S.E., Hofheinz, R.D., Pauligk, C., Kopp, H.-G., Haag, G.M., Luley, K.B., Meiler, J., Homann, N., Lorenzen, S., Schmalenberg, H., Probst, S., Koenigsmann, M., Egger, M., et al.: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capeciatbine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Lancet Oncol (2016), published online October 21, 2016: http://dx.doi.org/10.1016/S1470-2045(16)30531-9
  • Probst, S.: Nicht alles ist machbar und nicht alles muß gemacht werden. (Buchkapitel) In: Klapheck, E. (Hg.): Kerrnfragen 1: Jüdische Positionen zur Sterbehilfe. Berlin 2016, S. 17-59
  • Inhestern, J., Oertel, K., Stemmann, V., Schmalenberg, H., Dietz, A., Rotter, N., Veit, J., Görner, M., Sudhoff, H., Junghanß, C., Wittekindt, C., Pachmann, K., Gutinas-Lichius, O.: Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cancer PLOS ONE (2015);  DOI: 10.1371/journal.pone.0132901

Im Jahr 2015

  • Pauligk C., Tannpafel A., Meiler J., Luley K.B., Kopp H.-G., Homann N., Hofheinz R.D., Schmalenberg H., Probst S., Haag G.M., et.al.:
    Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of  the FLOT4  phase III study of the AIO.
    J Clin Oncol 33, 2015 (suppl; abstr. 4016)
  • Yilmaz-Aslan, Y., Annett-Horn, A., Gök, Y., Probst, S., Brzoska, P.: Palliativversorgung bei Menschen mit Migrationshintergrund: Optimierungspotenziale aus Sicht von Gesundheitspersonal
    Oncol Res Treat 2015; 38 (suppl 2):18  

Im Jahr 2014:

  • Oettle H., Riess H., Stieler JM., Heil G., Schwaner I., Seraphin J., Görner M., Mölle M., et al.:
    Second-line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folic Acid and Fluorocil Alone for Gemcitabine-Refratory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
    J Clin Oncol. 2014 Aug 10; 32(23):2423-2429. Epub 2014 Jun 30.
  • Herth I., Dietrich S., Benner A., Hegenbarth U., Rieger M., Stadtherr P., Bondong A., Tran TH., Weide R., Hensel M., Knauf W., Franz-Werner J., Welslau M., Procaccianti M., Görner M., Meissner J., Luft T., Schönland S., Witzens-Harig M., Zenz T., Ho AD., Dreger P.:
    The Impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison
    Ann Oncol. 2014 Jan; 25(1):200-6. Doi: 10.1093/annonc/mdt511

Im Jahr 2013:

  • Linnemann T., Müller F., Löhnert M., Hirnle P., Görner M.:
    Successful treatment of paraneoplastic hypercalcemia in a patient with giant condyloma acuminatum: a case report
    J Med Case Rep, 2013 Nov 7; 7:251. Doi 10.1186/1752-1947-7-251
  • Wegehenkel K., Görner M.:
    69-jähriger Patient: Temsirolimus bei progredientem Mantelzell-Lymphom mit Orbitabefall und Zweitmalignom.
    Thieme Case Report, 2013; 1, 13-15
  • Pauligk C, Meiler J, Hofheinz D, Kopp H-G, Mayer F, Schmalenberg H, Luley K, Haag GM, Schmiegel WH, Homann N, Probst S, Königsmann M, Prasnikar N, Trojan J, Egger M, Mahlberg R, Heike M, Tannapfel A, Jäger E, Al-Batran SE:
    Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study
    J Clin Oncol 31, 2013 (suppl; abstr 4079)
  • Görner M., Brasch F., Hirnle P., Gehl H.B., Scholtz L.U., Wegehenkel K., Sudhoff H.: Multimodality treatment for poorly differentiated neuroendocrine head an neck carcinomas – a single institution experience.
    Eur J Cancer Care, 2013 May 23. doi: 10.1111/ecc.12070. (Epub ahead of print)

Im Jahr 2012:

  • Al-Batran S.E., Pauligk C., Homann N., Hartmann J.T., Moehler M., Probst S., Rethwisch V., Stoehlmacher-Williams J., Prasnikar N., Hollerbach S., Bokemeyer C., Mahlberg R., Hofheinz R.D., Luley K., Kullmann F., Jäger E.:
    The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
    Eur J Cancer, 2012 Oct 11. pii: S0959-8049 (12)00750-2 doi: 10.1016/j.ejca2012.09.025 (Epub ahead of print)
  • Hozaeel W., Hofheinz R., Homann N., Illerhaus G., Martens U., Stoelmacher J., Schmalenberg H., Luley K., Prasnikar N., Egger M., Probst S., Fischbach W., Moening S., Hoelscher A.:
    Characteristics of patients with limited metastatic gastric cancer in the FLOT3 trial.
    Onkologie 2012; 35(suppl 6): 165
  • Koock U., Pauligk C., Luley K.B., Mayer F., Schulmann K., Homann N., Schmalenberg H., Hozaeel W., Hofheinz R., Probst S., Mahlberg R., Königsmann M., Haag G.M., et al.:
    Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO
    J Clin Oncol 30, 2012 (suppl; abstr. 4083)
  • Al-Batran S.E., Hofheinz R., Homann N., Illerhaus G., Martens U.M., Stöhlmacher-Williams J., Schalenberg H., Luley K.B., Prasnikar N., Egger M., Probst S., Hartmann J.T., Möhler M.H., Arnold D., Fischbach W., Pauligk C et al.:A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3.
    J Clin Oncol 30, 2012 (suppl; abstr. 4090)
  • Riesenberg H., Müller F., Görner M.: Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report.
    J Med Case Rep. 2012 Jul 19;6 (1): 211

Im Jahr 2011:

  • Müller F., Riesenberg H., Hirnle P., Gehl H.-B., Düwel P., Görner M.:Komplette Remission multifokaler zerebraler Metastasen bei chemotherapierefraktärem NSCLC durch Monotherapie mit Gefitinib
    Strahlentherapie und Onkologie 2011;12, 826-830
  • Sudhoff H.H., Schwarze H.P., Winder D., Steinstraesser L., Görner M.: Evidence for a causal association for HPV in head and neck cancers
    European Archieves of Oto-Rhino-Laryngology, 2011, 268 (11): 1541-1547
  • Al-Batran S., Hofheinz R., Homann N., Illerhaus G., Martens U., Stöhlmacher-Williams J., Schmalenberg H., Luley K., Egger M., Probst S., Hartmann J.T., Arnold D., et al.: Definig two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    J Clin Oncol 29: 2011 (suppl; abstr 4070)

Im Jahr 2010:

  • Görner M., Seiwert T.Y., Sudhoff H.: Molecular targeted therapies in head and neck cancer - an update of recent developments
    Head Neck Oncol. 2010, (14) 2-8
  • Al-Batran S.E., Homann N., Hartmann J.T., Möhler M., Pauligk C., Probst S., et al.: 5-fluorouracil, leucovorin and oxaliplatin with or without docetaxel in elderly  (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the AIO
    J Clin Oncol 28:15s, 2010 (suppl. abstr 4013)

Im Jahr 2009:

  • Goon P.K.C.,Stanley M.A., Ebmeyer J., Steinsträsser L., Upile T., Waseem J., Bernal-Sprekelsen M., Görner M., Sudhoff H.H.: HPV & head and neck cancer: a descriptive update.
    Head & Neck Oncology 2009; I:36 doi:10.1186/1758-3284-1-36
  • Görner, M., Riemer-Hommel P.:Ökonomische Auswirkungen unterschiedlicher adjuvanter Chemotherapieregime bei Patienten mit Kolonkarzinom im Stadium III
    Onkologie 2009; 32(11) 647
  • Al-Batran S.E., Homann N., Hartmann J.T., Möhler M., Pauligk C., Probst S., Rethwisch V., Prasnikar N., Wagner T., Jäger E.: 5-Fluorouracil, leucovorin and oxaliplatin with or without docetaxel in older adult patients with esophagogastric cancer: preliminary results from the FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Onkologie 2009; 32 (suppl 4): 135

Im Jahr 2008:

  • Görner M., Riemer Hommel P.: Adjuvant chemotherapy for colon cancer - analysis of treatment costs from the perspective of statutory sickness funds
    Z Gastroenterol. 2008 Jul; 46 (7): 681-688
  • Görner M., Just M., Gerull S.:Mammakarzinom im lokalisierten Stadium – Strategien für die systemisch-adjuvante Therapie
    Handchir Mikrochir Plast Chir, 2008 Aug; 40 (4): 230-238
  • Al-Batran S., Wirtz R.M., Pauligk C., Steinmetz K., Probst S., Hartmann J.T. et al.:Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first line chemotherapy
    J Clin Oncol 26: 2008 (suppl; abstr. 4544)
  • Pauligk C., Wirtz R., Steinmetz K., Probst S., Hartmann J.T., Hofheinz R., Homann N. et al.: The prognostic role of the epidermal growth factor receptor (EGFR) in patients with  metastatic gastric cancer.
    J Clin Oncol 26: 2008 (suppl; abstr.22033)
  • Al-Batran S.E., Hartmann J.T., Probst S., Schmalenberg H., Hollenbach S. et al.: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin
    J Clin Oncol. 2008 Mar 20; 26(9): 1435-1442
  • Al-Batran S.E., Hartmann J.T., Hofheinz R., Homann N., Rethwisch V., Probst S., et al: Biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction
    Ann Oncol. 2008 Nov;19 (11): 1882-1887
  • Görner M., Gerull S., Schäfer E., Just M., Sure M., Hirnle P.: Painful spinal cord compression as a complication of extramedullary hematopoiesis associated with beta-thalassemia intermedia
    Strahlenther Onkol., 2008 Apr; 184 (4) 224-226
  • Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Görner M., Mölle M., Hilbig A., Dörken B., Riess H., Oettle H.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
    Onkologie 2008; 31 (suppl 4): 147
  • Görner M., Späth-Schwalbe E., Task Force Geriatrische Onkologie of the DGHO, ÖGHO, DGG and AIO: Modern treatment options for elderly patients with multiple myeloma
    Onkologie. 2008 Jun; 31 (6): 335-342

Im Jahr 2007:

  • Al-Batran S.E., Hartmann J.T., Hofheinz R., Probst S., Seipelt G., Homann N., Schuch G.: Fortgeschrittenes Magenkarzinom
    Onkologisch 3/2007: 10-11
  • Hartmann J.T., Hofheinz R., Clemens M.R., Homann N., Probst S., Pauligk C. Stöhlmacher J et al.: Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
    Onkologie, 2007: 30 (suppl 3):139
  • Luft T., Conzelmann M., Benner A., Rieger M., Hess M., Strohhaecker U., Görner M., Hegenbart U., Ho A.D., Dreger P.: Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease
    Blood 2007, Dec 15; 110 (13): 4535-4542

Im Jahr 2006:

  • Späth-Schwalbe E., Görner M.: Behandlung des multiplen Myeloms bei älteren Patienten
    Onkologie heute 2006; (6) 29-34
  • Schneider M., Munder M., Karakhanova, Ho A.D., Görner M.: The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation
    Clin Lab Haematol. 2006 Dec; 28 (6): 382-390
  • Luft T., Rodionova E., Maraskovsky E., Kisch M., Hess M., Buchholz C., Görner M.: Adaptive functional differentiation of dentritic cells: integrating the network of extra- and intracellular signals
    Blood. 2006 jun 15; 197 (12): 4763-4769
  • Karakhanova S., Munder M., Schneider M., Bonyhadi H., Ho A.D., Görner M.: Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease
    J Immunother. 2006 May-Jun; 29 (3): 336-349
  • Al-Batran S., Hartmann J.T., Probst S., Hofheinz R., Stöhlmacher J. et al.: A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
    J Clin Oncol, 2006; 24 (suppl. abstr. LBA4016)
  • Platzbecker U., Thiede C., Füssel M., Geissler G., Illmer T., Mohr B., Hänel M., Mahlberg R., Krümpelmann U., Weissinger F., Schaich M., Theuser C., Ehninger G. und Bornhäuser M.: Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia
    Leukemia, 2006, 20, 707-714

Im Jahr 2005:

  • Gerull S., Görner M., Benner A., Hegenbart U. et al.: Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma
    Bone Marrow Transplant 2005; 36: 963-969
  • Raab M.S., Cremer F.W., Breitkreutz I.N., Gerull S., Luft T., Benner A., Görner M., Ho.A.D.: Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma
    Ann Oncol. 2005 Apr; 16 (4): 611-617
  • Munder M., Mollinedo F., Calafat J., Canchado J., Gil-Lamaignere C., Fuentes J.M., Luckner C., Doschko G., Soler G., Eichmann K., Müller F.M., Ho A.D., Görner M.: Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity
    Blood, 2005 Mar 15; 195 (6): 2549-2556
  • S. Al-Batran, Stöhlmacher J., Probst S., Hollerbach G., Wilhelm G., Derigs H.,  Seipelt G., Kojouharoff G., Graubnaer A., Hinke A., Jäger E.: Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluororuracil, leucovorin and cisplatin (FLP) as a first line thearpy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study
    J Clin Oncol, 2005, 23 (suppl. may, abstr. 4015)
  • Bay J.O., Dhedin N., Görner M., Vannier J.P., Marie-Cardine A., Stamatuollas A. et al.: Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies
    Transplantation, 2005, Sep. 27; 80 (6): 782-788
  • Jahnke K., Thiel E., Schilling A., Herrlinger U., Weller M., Coupland S.E., Krümpelmann U. et al.: Low-grade primary central nervous system lymphoma in immunocompetent patients
    Br J Haematol 2005 Mar; 128 (5): 616-624
  • Seebach J.D., Stussi G., Passweg J.R., Loberiza FR, Gajewski J.L., Keating A., Görner M., et al.: ABO blood group barrier in allogeneic bone marrow transplantation revisted
    Biol Blood Marrow Transplant. 2005 Dec; 11 (12): 1006-1013

Im Jahr 2004:

  • Luft T., Maraskovsky E., Schnurr M., Knebel K., Kirsch M., Görner M., Skoda R., Ho A.D., Mawroth P., Bierhaus A.: Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells
    Blood. 2004 Aug 15; 104 (4): 1066-1074

Im Jahr 2003:

  • Proske S., Görner M., Schnuch A., Hartschuh W.: Analfissuren unter aggressiver Chemotherapie
    Coloproctology, 2003, 25 (2): 106-112
  • Gerull S., Probst S., Ho A.D., Goldschmidt H., Görner M.,  Schäfer H.: Non-myeloablative allogeneic
    transplantation in patients with high-risk multiple myeloma
    Blood 2003 Nov., 102 (11): 475b
  • Kornacker M., Ipek Y., Probst S., Krasniqi F., Villalobos M, Haas R., Hensel M., Ho A.D.: Long  term relapse free survival is possible after autologous transplantation for follicular lymphoma
    Blood 2003 Nov., 102 (11): 733a
  • Thomasson B., Peterson L., Thompson J., Görner M., Kiem H.P.: Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stem cells in dogs
    Hum Gene Ther. 2003 Nov 20; 14 (17): 1683-1686
  • Höpfner S., Görner M., Benner A., Henning P., Ho A.D.: Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation
    J Hematother Stem Cell Rex., 2003 Jun; 12 (3): 331 -339
  • Görner M., Weber-Nordt R., Höpfner S., Benner A., Luft T., Ho A.D.: Addition of a low fixed number of CD3+ cells to CD34- enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation
    J Hematother Stem Cell Rex., 2003 Jun; 12 (3): 309-320
  • Leo E., Görner M., Krämer A., Ho A.D.: Niedrig- und intermediärmaligne Non-Hodgkin-Lymphome
    Onkologisch 3/2003: 11-15
  • Luft T., Moos M., Goldschmidt H., Ho A.D., Görner M.: Dissociation of putative graf-versus-hematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma
    Br J Haematol. 2003 Nov; 123 (4): 646-653